Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.84

+1.8%

Dec 19 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (9215)	9/28/2003 8:49:21 AM
From: Icebrg	Read Replies (1) of 52153

UBS Global Life Sciences Conference. I have just listened to one and a half hours' worth of Oncology Panel discussion (centering on colorectal cancer), which I found to be extremely interesting. event.streamx.us A couple of subjects that came up: - Avastin and the potential impact this drug may have on future treatment regimens for colorectal cancer. - concerns about the ever increasing costs for the healthcare system. Not only are drugs getting more expensive. More drugs are used in combinations. More drugs will be needed to counter side-effects. And more patients survive for longer periods and will therefore be using more drugs during their treatment. - considerations on what could be considered as clinically relevant improvements. - a general expression of "distrust" as far as reported early stage trial results are concerned. For example: Patients with a very good performance status are normally recruited into open label non-randomized phase II trials. One of the docs quoted an example where such an early trial gave a "response rate" of 60 %, while in a later large randomized phase III trial no benefits at all were observed. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next